Montelukast Pharmathen S.A.

Montelukast, the active ingredient in Montelukast Pharmathen S.A., is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage chronic asthma and allergic rhinitis, helping to reduce airway inflammation and nasal symptoms in patients of all ages. The medication works by blocking specific leukotriene receptors that contribute to bronchoconstriction and allergic responses.

GNH USA supplies Montelukast Pharmathen S.A. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway diseases. - Asthma: reduces frequency of exacerbations and improves lung function in persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Nausea: transient gastrointestinal upset. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, suicidal thoughts, or behavioral disturbances. - Hepatic enzyme elevation: signs of liver dysfunction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control: ensure baseline therapy is optimized. - Monitor mood: watch for depression or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be needed. - Avoid in patients with known hypersensitivity to montelukast or excipients. - Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma levels. - Strong CYP inducers (e.g., rifampicin, phenobarbital): may reduce therapeutic effect. - Concurrent use with other leukotriene modifiers: risk of additive adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Beta‑agonists: possible additive bronchodilator effect, monitor respiratory status.